Track topics on Twitter Track topics that are important to you
Long-term Canakinumab Treatment Lowering Inflammation Independent of Lipid Levels for Residual Inflammatory Risk Benefit – Personalized Medicine for Recurrent MI, Strokes and Cardiovascular Death Reporter: Aviva Lev-Ari, PhD, RN Major findings from the trial were presented earlier this year. The trial was designed to test whether canakinumab, which lowers inflammation independe...
SANTA CLARA, Calif., Nov. 21, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces the publication of two new papers. These joint public...
Study shows that dog owners had a lower risk of death due to cardiovascular disease or to other causes
New research suggests greater amounts of high-density lipoprotein (HDL)
BergaMet NA’s bergamot-based cardiovascular health supplements will soon be available on health, wellness and beauty product e-commerce site VitaBeauti.com. BOCA RATON, Fla. (PRWEB) November 20, 2017 BergaMet NA’s bergamot-based cardiovascular health supplements will soon be available on health, wellness and beauty product e-commerce site VitaBeauti.com. A bergamot is a citrus fruit thought ...
A novel AMP-activated protein kinase activator showed glucose reduction and decreased cardiovascular risk factors in people with type 2 diabetes in a phase 2a trial, according to a press release from the drug’s developer.The first-in-class drug (O304, Betagenon/Baltic Bio) activates AMP-activated protein kinase (AMPK), which regulates energy balance. By activating this protein, the researchers a...
Owning a dog could be linked to a decreased risk of
Stem cell technology innovator continues rapid growth, plans further global expansion to become the global leader in hiPSC-based drug discovery & development solutions Ncardia, an emerging drug discovery and development stem cell technology company whose mission is to deliver cardiac and neural solutions based on its best-in-class human induced plu...
Amish men and women who carried a genetic mutation appeared to be in better cardiovascular health and had longer telomeres, a barometer of longevity.
LUMEDX Corporation, a cardiovascular data intelligence and information systems (CVIS) company, will present the latest in CV imaging, data management and next generation analytics solutions at the 103rd Scientific Assembly and Annual Meeting of the Radiological Society of North America this month (Booth #6235). LUMEDX says that they will showcase ...
WESTMINSTER, Colo., Nov. 16, 2017 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced the European Patent Office’s issuance of a patent (EPO # 2515899) on methods of treating cardiovascular disease and conditions with a thiol-substi...
As a specialist in women’s
Ingelheim, Germany : New data showed that empagliflozin reduced the risk of cardiovascular death compared with placebo when added to standard of care in adults with type 2 diabetes and peripheral artery disease. These results, from a post-hoc analysis of the landmark EMPA-REG OUTCOME trial, were shared as an oral presentation on behalf of Boehringer Ingelheim and Eli Lilly and Company at the Ameri...
The Global Cardiovascular Devices Market Research Report Forecast 20172021 is a valuable source of insightful data for business strategists. It provides the Cardiovascular Devices industry overview with growth analysis and historical futuristic cost, revenue, demand and supply data as applicable. The research analysts provide an elaborate description of the value chain and its distributor analy...
Hypertrophic Cardiomyopathy Pipeline Review, H2 2017SummaryGlobal Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypertrophic Cardiomyopathy Pipeline Review, H2 2017, provides an overview of the Hypertrophic Cardiomyopathy Cardiovascular pipeline landscape.Hypertrophic cardiomyopathy HCM is a disease in which the heart muscle myocardium becomes abnormally thick hype...
Data from Amgen's Fourier study supports the use of Repatha to reduce the risk of recurrent cardiovascular events in patients with a history of multiple heart attacks.
People who regularly eat nuts have a reduced risk of
NewsThe phase III results and analysis suggest that in the future, physicians may be able to identify patients who can achieve the greatest cardiovascular benefit from long-term canakinumab treatment.
BEDMINSTER, N.J. and DUBLIN, Ireland, Nov. 14, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced data analysis orally presented today at the American Heart Association (AHA) 2017 Scientific Sessions in Anaheim, California. The oral presentat...
These results highlight Repatha's ability to reduce the residual risk for CV events particularly in high-risk patients with limited treatment options.
Jardiance® reduced risk of cardiovascular death in adults with type 2 diabetes and peripheral artery disease
GlyCardial Diagnostics believes it has the technology to prevent premature myocardial infarctions, 80% of which are preventable. Barcelona-based GlyCardial Diagnostics is a biotech, which spun-out from the Catalan Institute of Cardiovascular Science. The startup focuses on the development of an in vitro ... This awesome article Spanish Biotech Gets €2.4M to Spot Myocardial Infarction Before it...
In the United States, postpartum hemorrhage accounts for 11.4% of maternal deaths, the fourth most common cause after cardiovascular diseases, non-cardiovascular diseases, and infection; worldwide, it is the leading cause of maternal mortality. This feature will discuss the latest treatments for managing postpartum hemorrhage.
Vaginal estrogen may improve vaginal symptoms of menopause and does not increase the risk for endometrial cancer, stroke, or cardiovascular disease.